Hedge Funds Are Selling Sunesis Pharmaceuticals, Inc. (SNSS)

Insider Monkey has processed numerous 13F filings of hedge funds and successful value investors to create an extensive database of hedge fund holdings. The 13F filings show the hedge funds’ and successful investors’ positions as of the end of the first quarter. You can find articles about an individual hedge fund’s trades on numerous financial news websites. However, in this article we will take a look at their collective moves over the last 4.5 years and analyze what the smart money thinks of Sunesis Pharmaceuticals, Inc. (NASDAQ:SNSS) based on that data and determine whether they were really smart about the stock.

Sunesis Pharmaceuticals, Inc. (NASDAQ:SNSS) has experienced a decrease in support from the world’s most elite money managers of late. SNSS was in 11 hedge funds’ portfolios at the end of the first quarter of 2020. There were 12 hedge funds in our database with SNSS holdings at the end of the previous quarter. Our calculations also showed that SNSS isn’t among the 30 most popular stocks among hedge funds (click for Q1 rankings and see the video for a quick look at the top 5 stocks).

Video: Watch our video about the top 5 most popular hedge fund stocks.

So, why do we pay attention to hedge fund sentiment before making any investment decisions? Our research has shown that hedge funds’ small-cap stock picks managed to beat the market by double digits annually between 1999 and 2016, but the margin of outperformance has been declining in recent years. Nevertheless, we were still able to identify in advance a select group of hedge fund holdings that outperformed the S&P 500 ETFs by more than 58 percentage points since March 2017 (see the details here). We were also able to identify in advance a select group of hedge fund holdings that underperformed the market by 10 percentage points annually between 2006 and 2017. Interestingly the margin of underperformance of these stocks has been increasing in recent years. Investors who are long the market and short these stocks would have returned more than 27% annually between 2015 and 2017. We have been tracking and sharing the list of these stocks since February 2017 in our quarterly newsletter. Even if you aren’t comfortable with shorting stocks, you should at least avoid initiating long positions in stocks that are in our short portfolio.

Israel Englander of Millennium Management

At Insider Monkey we scour multiple sources to uncover the next great investment idea. There is a lot of volatility in the markets and this presents amazing investment opportunities from time to time. For example, this trader claims to deliver juiced up returns with one trade a week, so we are checking out his highest conviction idea. A second trader claims to score lucrative profits by utilizing a “weekend trading strategy”, so we look into his strategy’s picks. We read hedge fund investor letters and listen to stock pitches at hedge fund conferences. We recently recommended several stocks partly inspired by legendary Bill Miller’s investor letter. Our best call in 2020 was shorting the market when the S&P 500 was trading at 3150 in February after realizing the coronavirus pandemic’s significance before most investors. Keeping this in mind let’s view the new hedge fund action encompassing Sunesis Pharmaceuticals, Inc. (NASDAQ:SNSS).

How have hedgies been trading Sunesis Pharmaceuticals, Inc. (NASDAQ:SNSS)?

At the end of the first quarter, a total of 11 of the hedge funds tracked by Insider Monkey held long positions in this stock, a change of -8% from the fourth quarter of 2019. On the other hand, there were a total of 11 hedge funds with a bullish position in SNSS a year ago. So, let’s review which hedge funds were among the top holders of the stock and which hedge funds were making big moves.

According to publicly available hedge fund and institutional investor holdings data compiled by Insider Monkey, Wilmot B. Harkey and Daniel Mack’s Nantahala Capital Management has the biggest position in Sunesis Pharmaceuticals, Inc. (NASDAQ:SNSS), worth close to $4 million, comprising 0.1% of its total 13F portfolio. Coming in second is Biotechnology Value Fund / BVF Inc, led by Mark Lampert, holding a $2.6 million position; 0.2% of its 13F portfolio is allocated to the stock. Other members of the smart money that are bullish comprise Srini Akkaraju and Michael Dybbs’s Samsara BioCapital, Ken Griffin’s Citadel Investment Group and Mark Hart III’s Corriente Advisors. In terms of the portfolio weights assigned to each position Samsara BioCapital allocated the biggest weight to Sunesis Pharmaceuticals, Inc. (NASDAQ:SNSS), around 1.42% of its 13F portfolio. Corriente Advisors is also relatively very bullish on the stock, earmarking 1.35 percent of its 13F equity portfolio to SNSS.

Because Sunesis Pharmaceuticals, Inc. (NASDAQ:SNSS) has witnessed a decline in interest from hedge fund managers, it’s safe to say that there exists a select few hedge funds who were dropping their entire stakes by the end of the first quarter. At the top of the heap, Israel Englander’s Millennium Management dumped the largest position of the “upper crust” of funds followed by Insider Monkey, valued at close to $0.1 million in stock. Peter Algert and Kevin Coldiron’s fund, Algert Coldiron Investors, also dumped its stock, about $0 million worth. These bearish behaviors are important to note, as aggregate hedge fund interest fell by 1 funds by the end of the first quarter.

Let’s also examine hedge fund activity in other stocks – not necessarily in the same industry as Sunesis Pharmaceuticals, Inc. (NASDAQ:SNSS) but similarly valued. These stocks are Oncternal Therapeutics, Inc. (NASDAQ:ONCT), Hunt Companies Finance Trust, Inc. (NYSE:HCFT), Cyren Ltd (NASDAQ:CYRN), and Yatra Online, Inc. (NASDAQ:YTRA). This group of stocks’ market valuations are similar to SNSS’s market valuation.

View table here if you experience formatting issues.

As you can see these stocks had an average of 4.5 hedge funds with bullish positions and the average amount invested in these stocks was $4 million. That figure was $13 million in SNSS’s case. Yatra Online, Inc. (NASDAQ:YTRA) is the most popular stock in this table. On the other hand Oncternal Therapeutics, Inc. (NASDAQ:ONCT) is the least popular one with only 2 bullish hedge fund positions. Compared to these stocks Sunesis Pharmaceuticals, Inc. (NASDAQ:SNSS) is more popular among hedge funds. Our calculations showed that top 10 most popular stocks among hedge funds returned 41.4% in 2019 and outperformed the S&P 500 ETF (SPY) by 10.1 percentage points. These stocks gained 12.3% in 2020 through June 30th and still beat the market by 15.5 percentage points. Unfortunately SNSS wasn’t nearly as popular as these 10 stocks and hedge funds that were betting on SNSS were disappointed as the stock returned -36.6% during the second quarter and underperformed the market. If you are interested in investing in large cap stocks with huge upside potential, you should check out the top 10 most popular stocks among hedge funds as most of these stocks already outperformed the market in 2020.

Disclosure: None. This article was originally published at Insider Monkey.